Gottlieb: FDA Would Be Subject To More White House Control Under A Second Trump Term

 
• By Sarah Karlin-Smith

The former commissioner warned that the FDA likely would get very different treatment under a second Trump term than it got under a first. Gottlieb also discussed the need for legislation to help advance ‘n of 1’ drug regulation and how to communicate uncertainty in a wide-ranging interview.

Former FDA Commissioner Scott Gottlieb is interviewed at a 1 February Friends of Cancer Research Event
Former FDA Commissioner Scott Gottlieb was interviewed 1 February at a Friends of Cancer Research diagnostic policy event. • Source: Friends of Cancer Research/YouTube

More from Legislation

More from Pink Sheet